Last reviewed · How we verify
Timolol 0.25% Ophthalmic Solution
Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.
Timolol is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | Timolol 0.25% Ophthalmic Solution |
|---|---|
| Sponsor | Keith G. LeBlanc, Jr, MD |
| Drug class | Beta-adrenergic antagonist (non-selective beta-blocker) |
| Target | Beta-1 and beta-2 adrenergic receptors |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Timolol blocks beta-1 and beta-2 adrenergic receptors in the ciliary body of the eye, which reduces the rate of aqueous humor secretion. This leads to a decrease in intraocular pressure, making it effective for treating conditions characterized by elevated eye pressure. The ophthalmic solution formulation allows direct topical application to the eye for local therapeutic effect.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Ocular irritation or discomfort
- Blurred vision
- Conjunctivitis
- Systemic beta-blocker effects (bradycardia, bronchospasm) with topical absorption
Key clinical trials
- Topical Timolol: a Comparison of Surgical Outcomes (PHASE2)
- Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves (PHASE4)
- Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension (PHASE3)
- Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Timolol 0.25% Ophthalmic Solution CI brief — competitive landscape report
- Timolol 0.25% Ophthalmic Solution updates RSS · CI watch RSS
- Keith G. LeBlanc, Jr, MD portfolio CI